The 36-month beta value for NKTX is also noteworthy at 0.73. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for NKTX is 52.16M, and at present, short sellers hold a 13.48% of that float. The average trading volume of NKTX on June 19, 2025 was 1.15M shares.
NKTX) stock’s latest price update
The stock of Nkarta Inc (NASDAQ: NKTX) has increased by 0.55 when compared to last closing price of 1.81.Despite this, the company has seen a loss of -9.00% in its stock price over the last five trading days. globenewswire.com reported 2025-06-06 that SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space.
NKTX’s Market Performance
Nkarta Inc (NKTX) has experienced a -9.00% fall in stock performance for the past week, with a 7.06% rise in the past month, and a 19.74% rise in the past quarter. The volatility ratio for the week is 2.76%, and the volatility levels for the past 30 days are at 3.53% for NKTX. The simple moving average for the past 20 days is -0.37% for NKTX’s stock, with a -31.79% simple moving average for the past 200 days.
Analysts’ Opinion of NKTX
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see NKTX reach a price target of $14. The rating they have provided for NKTX stocks is “Buy” according to the report published on October 09th, 2024.
Raymond James gave a rating of “Strong Buy” to NKTX, setting the target price at $16 in the report published on August 14th of the previous year.
NKTX Trading at -1.99% from the 50-Day Moving Average
After a stumble in the market that brought NKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTX starting from Shook David, who sale 8,638 shares at the price of $2.20 back on Jan 15 ’25. After this action, Shook David now owns 190,955 shares of Nkarta Inc, valued at $19,004 using the latest closing price.
Levin Alyssa, the of Nkarta Inc, sale 5,838 shares at $2.20 during a trade that took place back on Jan 15 ’25, which means that Levin Alyssa is holding 102,662 shares at $12,844 based on the most recent closing price.
Stock Fundamentals for NKTX
The total capital return value is set at -0.29. Equity return is now at value -26.10, with -21.24 for asset returns.
Based on Nkarta Inc (NKTX), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -1.28.
Currently, EBITDA for the company is -99.64 million with net debt to EBITDA at -0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.48.
Conclusion
In summary, Nkarta Inc (NKTX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
